Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429625 | 0.85 | F10 (0.44) | F10PDK1PDK2PDK3PDK4 | |
| SCHEMBL14429624 | 0.83 | F10 (0.39) | F10ROCK2PDK1PDK2PDK3 | |
| SCHEMBL14269343 | 0.81 | F10 (0.53) | F10 | |
| SCHEMBL5459404 | 0.81 | NAMPT (0.45) | NAMPTF10JAK1ROCK2PDK1 | |
| SCHEMBL5459134 | 0.77 | F10 (0.44) | F10 | |
| SCHEMBL8298724 | 0.77 | F10 (0.51) | F10 | |
| SCHEMBL5710344 | 0.77 | F10 (0.44) | F10 | |
| SCHEMBL5459180 | 0.77 | F10 (0.72) | F10 | |
| SCHEMBL5459186 | 0.77 | F10 (0.72) | F10 | |
| SCHEMBL4858641 | 0.76 | SRD5A1 (0.43) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | TFPI, F2, F12 | NAMPT 614/4885F10 13/4885NPY5R 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.